Univest
Univest
  • Markets

Top 3 Hospital Stocks to Watch in 2027: Apollo Hospitals, Medanta and Narayana Health

  • November 19, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Top 3 Hospital Stocks to Watch in 2027: Apollo Hospitals, Medanta and Narayana Health

Apollo Hospitals Rs 8,777.00, Q2 PAT +33.5%. Medanta Rs 1,436.60, Q2 PAT +38.3%. Narayana Health Rs 1,882.00, Q2 PAT +16.5%. Prices as of 18 Nov 2026.

Quick Answer

The hospital stocks to watch in 2027 are Apollo Hospitals Enterprise, Global Health (Medanta) and Narayana Hrudayalaya, based on their latest results, returns and balance sheets. Medanta leads on recent profit growth, Narayana Health is the most attractively valued, and Apollo Hospitals earns the highest return on equity. The best figures in the group are 38.3% quarterly profit growth, a PE of 44.97 and a return on equity of 21.14%. Each stock has its own risks, so investors should match the choice to their holding period and risk appetite.

The hospital stocks to watch in 2027 are best picked on reported numbers. Rising health insurance cover, new hospital beds and higher revenue per bed are lifting India’s listed hospital chains, and the three on this list grew revenue by more than 22% in the September 2026 quarter.

This list covers Apollo Hospitals Enterprise, Global Health (Medanta) and Narayana Hrudayalaya. Each company is assessed on quarterly and annual profit growth, return on equity, debt, valuation and where its share price sits in its 52-week range. Prices are as of the 18 November 2026 close.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Top 3 Hospital Stocks to Watch in 2027 at a Glance
  • Why Are These the Hospital Stocks to Watch in 2027?
  • What Could Drive Hospital Stocks in 2027?
  • 1. Apollo Hospitals Enterprise: Largest Integrated Hospital Network
    • Apollo Hospitals Financial Performance
    • What to Watch in Apollo Hospitals for 2027
  • 2. Global Health (Medanta): Super-Speciality Care in North India
    • Medanta Financial Performance
    • What to Watch in Medanta for 2027
  • 3. Narayana Hrudayalaya: Affordable Care with a Lower PE
    • Narayana Health Financial Performance
    • What to Watch in Narayana Health for 2027
  • How Do Apollo Hospitals, Medanta and Narayana Health Compare?
  • Key Risks for Hospital Stocks in 2027
  • Conclusion
  • Frequently Asked Questions on Hospital Stocks to Watch in 2027
    • Which are the best hospital stocks to watch in 2027?
    • Which hospital stock has grown profit the fastest?
    • Which of these hospital stocks is the most attractively valued?
    • Which hospital stock has the lowest valuation?
    • What are the key risks for hospital stocks in 2027?
    • Should I invest in hospital stocks for the long term?

Top 3 Hospital Stocks to Watch in 2027 at a Glance

Apollo Hospitals, Medanta and Narayana Health have a combined market capitalisation of about Rs 2.04 lakh crore. The table below compares these hospital stocks to watch in 2027 on the metrics that matter most for long-term investors.

Metric Apollo Hospitals Medanta Narayana Health
Company Apollo Hospitals Enterprise Global Health (Medanta) Narayana Hrudayalaya
NSE Symbol APOLLOHOSP MEDANTA NH
Share Price (Rs) 8,777.00 1,436.60 1,882.00
52-Week Closing High (Rs) 9,069.00 1,508.90 2,080.30
52-Week Closing Low (Rs) 6,793.50 961.10 1,605.30
Market Cap (Rs Cr) 1,26,689 38,579 38,635
PE Ratio 54.20 62.93 44.97
ROE 21.14% 14.30% 17.17%
Debt to Equity 0.77 0.31 1.21
Dividend Yield 0.23% 0.03% 0.24%

On valuation, the stocks trade at the following PE ratios: Apollo Hospitals at 54.20 against an industry PE of 63.96; Medanta at 62.93 against an industry PE of 63.96; Narayana Health at 44.97 against an industry PE of 63.96. All three trade below their industry multiples, which leaves room for a re-rating if profit growth holds.

Why Are These the Hospital Stocks to Watch in 2027?

These three made the list of hospital stocks to watch in 2027 because of earnings delivery and balance sheet quality. Hospital stocks earn money from bed occupancy, the mix of complex procedures and the average revenue per occupied bed. Chains that add beds in under-served cities while keeping occupancy high tend to grow profits fastest.

In the September 2026 quarter, net profit grew 33.5% at Apollo Hospitals, 38.3% at Medanta and 16.5% at Narayana Health. Return on equity ranges from 14.30% to 21.14%, which shows how efficiently each company uses shareholder capital.

What Could Drive Hospital Stocks in 2027?

Hospital stocks in 2027 will be driven by new bed additions, occupancy at recently opened hospitals, insurance penetration and medical tourism. New hospitals usually take two to three years to reach mature margins, so expansion can weigh on near-term profits.

Apollo Hospitals is a constituent of the Nifty 50, so its results are also followed by index investors.

1. Apollo Hospitals Enterprise: Largest Integrated Hospital Network

Apollo Hospitals Enterprise runs India’s largest private hospital network and also owns Apollo Pharmacy, Apollo 24/7 digital health and Apollo Clinics.

Apollo Hospitals Financial Performance

Metric Latest Year Earlier Change
Revenue (Rs Cr) 7,659.70 6,243.30 +22.7%
Net Profit (Rs Cr) 659.50 494 +33.5%
Revenue FY26 vs FY25 (Rs Cr) 25,420.10 21,994.30 +15.6%
Net Profit FY26 vs FY25 (Rs Cr) 2,002.70 1,505.10 +33.1%

Net profit has compounded at about 16.1% a year from FY22 to FY26.

What to Watch in Apollo Hospitals for 2027

Apollo Hospitals grew FY26 net profit 33.1% to Rs 2,002.70 crore and September 2026 quarter profit 33.5% to Rs 659.50 crore. Its ROE of 21.14% is the highest of the three. Investors should track bed additions and the path to profitability in its digital business. The stock closed at Rs 8,777.00 on 18 November 2026, about 3.2% below its 52-week closing high of Rs 9,069.00 and 29.2% above its 52-week closing low of Rs 6,793.50.

2. Global Health (Medanta): Super-Speciality Care in North India

Global Health runs the Medanta chain of super-speciality hospitals in Gurugram, Lucknow, Patna, Indore and Ranchi, with a focus on complex procedures such as cardiac care, oncology and transplants.

Medanta Financial Performance

Metric Latest Year Earlier Change
Revenue (Rs Cr) 1,492.66 1,118.95 +33.4%
Net Profit (Rs Cr) 219.14 158.40 +38.3%
Revenue FY26 vs FY25 (Rs Cr) 4,508.86 3,771.29 +19.6%
Net Profit FY26 vs FY25 (Rs Cr) 554.07 481.32 +15.1%

For FY26, revenue came in at Rs 4,508.86 crore (+19.6%), and net profit rose 15.1% to Rs 554.07 crore. Net profit has compounded at about 29.6% a year from FY22 to FY26.

What to Watch in Medanta for 2027

Medanta grew September 2026 quarter net profit 38.3% to Rs 219.14 crore, the fastest in this group, and its net profit has grown in each of the last four years. Investors should track occupancy at its newer Lucknow and Patna hospitals. The stock closed at Rs 1,436.60 on 18 November 2026, about 4.8% below its 52-week closing high of Rs 1,508.90 and 49.5% above its 52-week closing low of Rs 961.10.

Compare Hospital Stocks on the Univest Screener

3. Narayana Hrudayalaya: Affordable Care with a Lower PE

Narayana Hrudayalaya runs the Narayana Health chain of hospitals across India and a hospital in the Cayman Islands, and it also offers health insurance products.

Narayana Health Financial Performance

Metric Latest Year Earlier Change
Revenue (Rs Cr) 2,895.53 1,667.78 +73.6%
Net Profit (Rs Cr) 301.15 258.50 +16.5%
Revenue FY26 vs FY25 (Rs Cr) 7,996.25 5,575.01 +43.4%
Net Profit FY26 vs FY25 (Rs Cr) 810.46 789.82 +2.6%

For FY26, revenue came in at Rs 7,996.25 crore (+43.4%), and net profit rose 2.6% to Rs 810.46 crore. Net profit has compounded at about 24.1% a year from FY22 to FY26.

What to Watch in Narayana Health for 2027

Narayana Health grew September 2026 quarter revenue 73.6% and net profit 16.5% to Rs 301.15 crore, and it has the lowest PE of the three at 44.97. Its debt-to-equity ratio of 1.21 is the highest in the group, so investors should track borrowing as it expands. The stock closed at Rs 1,882.00 on 18 November 2026, about 9.5% below its 52-week closing high of Rs 2,080.30 and 17.2% above its 52-week closing low of Rs 1,605.30.

How Do Apollo Hospitals, Medanta and Narayana Health Compare?

The table below puts quarterly growth, annual profit, valuation and price position for the three hospital stocks side by side.

Metric Apollo Hospitals Medanta Narayana Health
Q2 Net Profit Growth +33.5% +38.3% +16.5%
Latest Annual Net Profit (Rs Cr) 2,002.70 554.07 810.46
Net Profit CAGR (4 Years) 16.1% 29.6% 24.1%
PE vs Industry PE 54.20 vs 63.96 62.93 vs 63.96 44.97 vs 63.96
Distance from 52-Week Closing High 3.2% below 4.8% below 9.5% below

For investors building a list of hospital stocks to watch in 2027, the right pick depends on priorities. Those who want growth momentum may track Medanta, investors who want valuation comfort may prefer Narayana Health and investors who want capital efficiency may lean towards Apollo Hospitals.

Key Risks for Hospital Stocks in 2027

Even the strongest hospital stocks to watch in 2027 carry risks that investors should weigh before buying.

Expansion costs: New hospitals take time to fill beds, which can lower margins in the early years.

Price regulation: Caps on prices for drugs, devices or procedures can limit revenue growth.

Doctor talent: Hospital growth depends on attracting and keeping senior doctors, which raises costs.

Download the Univest iOS App or Univest Android App to track Apollo Hospitals, Medanta and Narayana Health live and get daily stock research.

Conclusion

Apollo Hospitals Enterprise, Global Health (Medanta) and Narayana Hrudayalaya stand out among hospital stocks to watch in 2027 on growth, returns and balance sheet strength. Before investing, compare each stock’s PE with its profit growth, check where it trades in its 52-week range, and track the December and March quarter results to confirm the trend into 2027. Building positions gradually suits a sector where earnings can swing with expansion costs.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Hospital Stocks to Watch in 2027

Which are the best hospital stocks to watch in 2027?

Ans. Apollo Hospitals Enterprise, Global Health (Medanta) and Narayana Hrudayalaya are three of the strongest hospital stocks to watch in 2027 based on reported numbers. Medanta leads on recent profit growth, Narayana Health is the most attractively valued, and Apollo Hospitals earns the highest return on equity. The strongest figures in the group are 38.3% quarterly profit growth, a 21.14% return on equity and a PE of 44.97. Each company covers a different part of the hospital space, so the best choice depends on whether an investor prefers growth, value or capital efficiency. Investors should match the pick to their own risk profile and holding period.

Which hospital stock has grown profit the fastest?

Ans. Global Health (Medanta) has grown profit the fastest among these three, with September 2026 quarter net profit up 38.3% year on year to Rs 219.14 crore. Apollo Hospitals follows with 33.5% growth. Over a longer period, Medanta’s net profit has compounded at about 29.6% a year from FY22 to FY26. Quarterly growth can swing with seasonality and one-time items, so investors should compare several quarters before drawing conclusions. Margins and demand trends over the next two quarters will show whether this pace can continue into 2027.

Which of these hospital stocks is the most attractively valued?

Ans. Narayana Hrudayalaya is the most attractively valued of the three, with a PE of 44.97 against an industry PE of 63.96. Apollo Hospitals trades at 54.20 and Medanta at 62.93. A lower PE can signal value, but it can also reflect slower growth or higher risk, so it should be read with profit growth and return on equity. Investors should also check where each stock trades within its 52-week range before deciding on an entry point.

Which hospital stock has the lowest valuation?

Ans. Narayana Hrudayalaya has the lowest valuation of the three with a PE of 44.97, against an industry PE of 63.96. Apollo Hospitals trades at 54.20 and Medanta at 62.93. All three trade below the industry multiple. Narayana also grew quarterly revenue 73.6%, but it carries more debt, with a debt-to-equity ratio of 1.21, so investors should weigh balance sheet strength along with valuation. Medanta has the highest PE of the three, which the market pays for its 38.3% quarterly profit growth and strong position in complex procedures.

What are the key risks for hospital stocks in 2027?

Ans. The main risks for hospital stocks in 2027 are expansion costs, price regulation and doctor talent. New hospitals take time to fill beds, which can lower margins in the early years. Caps on prices for drugs, devices or procedures can limit revenue growth. Hospital growth depends on attracting and keeping senior doctors, which raises costs. Investors should review quarterly results, avoid putting too much money into a single stock, and size positions according to their risk tolerance.

Should I invest in hospital stocks for the long term?

Ans. Hospital stocks can suit long-term investors who understand the sector’s cycles and are comfortable with price swings. Apollo Hospitals, Medanta and Narayana Health have shown profit growth and healthy returns on equity, which are good signs for long-term holders. Apollo Hospitals earns a 21.14% return on equity, which shows how efficiently it uses shareholder money. Building positions gradually, for example through staggered purchases, usually works better than buying a full position at once. Before investing, check your asset allocation and consider speaking with a SEBI-registered investment adviser.



Apollo Hospitals Healthcare stocks Hospital stocks Medanta Narayana Health
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply